Trial Results

Protocol
Available Languages: English
Statistical Analysis Plan
Available Languages: English

A Study of the Safety and Activity of Eculizumab in Pediatric Participants With Relapsing Neuromyelitis Optica Spectrum Disorder

Study Identifier:
ECU-NMO-303
ClinicalTrials.gov Identifier:
EudraCT Identifier:
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Other

Study Details

Medical Condition
  • Unmapped
Study Drug
  • Drug: Eculizumab
Date
Jan 2020 - Jul 2023
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: N/A - N/A
Requirements Information
Sex
Female & Male
Age
N/A - N/A

Study Details

Medical Condition
  • Unmapped
Study Drug
  • Drug: Eculizumab
Date
Jan 2020 - Jul 2023
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: N/A - N/A years
Requirements Information

Protocol Summary

The objective of this study is to evaluate the safety and efficacy of eculizumab in pediatric participants (aged 2 to \< 18 years) with relapsing neuromyelitis optica spectrum disorder (NMOSD).

Trial Locations

Location
Status
Location
Clinical Trial Site
San Francisco, California, United States, 94016
Status
N/A
Location
Clinical Trial Site
Washington, District of Columbia, United States, 20001
Status
N/A
Location
Clinical Trial Site
Miami, Florida, United States, 33101
Status
N/A
Location
Clinical Trial Site
Atlanta, Georgia, United States, 30301
Status
N/A
Location
Research Site
Baltimore, Maryland, United States, 21287
Status
N/A
Location
Clinical Trial Site
Rockville, Maryland, United States, 20847
Status
N/A